Colonics
About Me
Recent Posts
- New Journal Emphasizes Principles Of Injury, Function And Rehabilitation
- Pregnancy and fertility following bariatric surgery
- Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
- Home-based program to improve exercise and diet improves senior cancer survivors' physical function
- New Cause Of Fatal Brain Injury From Acute Viral Meningitis Discovered By Scripps Research Scientists
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
Friends
Links
Entry 1 of 437
Last Page | Next Page
1/22/2008
-
AIDS Healthcare Foundation criticizes Etravirine's pricing
|
AIDS Healthcare root (AHF) has urged Tibotec Pharmaceuticals Ltd., a dividing of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS. More: - Read More |
Post A Comment! :: Send to a Friend! |
Share and enjoy
